DMD and myeloid sarcoma: In the covariate‐adjusted analysis, where we adjusted the outcome model for age and sex and stratified by the matched set, the mortality risk was 28% less in persons with MS exposed to any DMD (HR: 0.72, 95% CI: 0.61–0.83, SE: 0.078) (Table 2).